Windlas Biotech Peer Comparison

NSE: WINDLAS | BSE: 543329

₹879.60

₹-30.05 (-3.30%)

As on 03-Nov-2026IST

Market cap

₹1,815 Cr

Revenue (TTM)

₹942 Cr

P/E Ratio

27.3

P/B Ratio

3.4

Div. Yield

0.7 %

Edit

	Windlas Biotech	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	1,815	18,204	17,954	17,370	16,335
Revenue (₹ Cr)	942	1,682	2,287	2,570	3,330
Net Profit (₹ Cr)	66.42	273.51	678.07	735.15	720.77
Net Margin (%)	6.92	16.19	28.10	26.88	21.60
RoE (%)	11.91	11.15	19.73	19.16	18.93
Price to Earnings	27.33	61.23	26.98	23.63	23.09
Price-To-Book	3.41	6.78	4.89	3.94	3.94

Income Statement (₹ Cr)

	Windlas Biotech	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Operating Revenue	904.09	1,538.87	2,187.19	2,519.65	3,129.42
Total Income	921.89	1,602.52	2,302.73	2,707.60	3,147.87
Total Expenditure	799.35	1,157.98	1,426.34	1,615.47	2,020.01
EBITDA	104.74	380.89	760.85	904.18	1,109.41
Depreciation	30.74	119.72	72.77	57.73	279.50
EBIT	74.00	261.17	688.08	846.45	829.91
Interest	4.83	58.79	0.87	9.57	192.67
Other Income	17.80	63.65	115.54	187.95	18.45
Exceptional Items	--	12.16	--	-49.16	-17.24
Profit before Tax	86.98	295.31	802.79	975.67	638.54
Provision for Tax	20.52	51.98	153.06	253.24	-8.97
Profit after Tax	66.46	243.33	649.73	722.43	647.51

	Windlas Biotech	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Shareholder's Funds	580.84	2,591.20	3,586.42	4,202.90	3,902.67
Minority Interest	--	1.04	44.38	--	-7.01
Non-Current Liabilities	5.13	249.46	20.75	19.19	1,149.84
Current Liabilities	320.93	848.06	385.96	627.48	2,201.22
Total Liabilities	907.35	3,705.61	4,037.51	4,921.88	7,246.72

	Windlas Biotech	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Non-Current Assets	280.05	2,578.95	1,451.85	1,046.35	5,582.75
Current Assets	626.85	1,109.77	2,585.66	3,803.22	1,663.97
Total Assets	907.35	3,705.61	4,037.51	4,921.88	7,246.72
Total Debt*	29.88	657.97	0.57	2.50	2,309.68
Net Current Assets	305.92	261.71	2,199.70	3,175.74	-537.25
Contingent Liabilities	--	160.01	17.53	370.49	51.57

	Windlas Biotech	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Cash From Operating Activities	104.93	342.18	523.24	967.57	537.99
Cash Flow from Investing Activities	-91.79	-325.92	-582.30	-561.67	-369.46
Cash from Financing Activities	-13.03	13.62	-46.46	-798.31	-313.53
Net Cash Inflow / Outflow	0.11	29.88	-105.52	-392.41	-145.00

	Windlas Biotech	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
ROCE (%)	16.06	11.43	24.97	23.39	14.47
ROE (%)	12.52	9.82	20.79	17.16	19.23
ROA (%)	7.97	6.97	17.94	14.91	9.18
EBIT Margin (%)	13.55	28.89	40.07	43.34	36.04
Net Margin (%)	7.21	15.18	28.22	26.68	20.57
Cash Profit Margin (%)	10.75	23.59	33.03	29.72	28.49

	Windlas Biotech	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Revenue Growth (%)	18.98	19.62	12.89	10.45	8.15
EBIT Growth (%)	9.29	29.72	17.90	19.68	8.91
Net Profit Growth (%)	8.96	210.81	20.08	-5.88	72.82
EPS Growth (%)	8.20	210.80	19.57	-5.88	73.16
Book Value Growth (%)	12.12	9.67	26.75	-0.34	36.71

	Windlas Biotech	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Price / Earnings	23.43	28.03	17.84	29.89	29.02
Price / Book Value	2.77	2.63	3.27	5.14	4.62
Dividend Yield (%)	0.85	0.17	0.53	1.59	0.00
EV/EBITDA	12.93	16.72	12.43	16.93	17.93
Market Cap (₹ Cr)	1,556.84	6,819.66	11,439.22	21,592.90	17,980.08

	Windlas Biotech	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debt to Equity	0.05	0.25	0.00	0.00	0.59
Short term debt to equity ratio	0.05	0.16	0.00	0.00	0.12
Current Ratio	1.95	1.31	6.70	6.06	0.76
Quick Ratio	1.76	0.88	5.59	5.31	0.56
Interest Coverage	19.02	6.02	923.75	102.95	4.31

	Windlas Biotech	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debtors to sales (%)	25.15	33.72	37.76	7.22	21.74
Asset Turnover	1.08	0.44	0.60	0.54	0.46
Receivable days	79.59	113.81	121.68	26.06	63.88
Inventory Days	28.91	84.76	63.83	65.95	43.27
Payable days	140.29	101.94	108.28	81.01	151.85
Cash Conversion Cycle	-31.79	96.62	77.23	11.00	-44.70

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.